Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 11Phase 1/2 6Phase 3 4

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 24Carcinoma, Renal Cell 15Stomach Neoplasms 9Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 6Kidney Neoplasms 5Carcinoma, Hepatocellular 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Mesothelioma 4Adenocarcinoma Of Esophagus 4Skin Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Anus Neoplasms 3Various Advanced Cancer 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Mesothelioma, Malignant 2Liver Neoplasms 2Hodgkin Disease 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma 2Anal Canal Carcinoma 2Adenocarcinoma 2von Hippel-Lindau Disease 1Uveal Melanoma 1

Interventions

Gemcitabine 28Cisplatin 26Mitomycin 18BCG Vaccine 12pembrolizumab 9Paclitaxel 8Doxorubicin 7Docetaxel 75-aminolevulinic acid hexyl ester 7apaziquone 6Carboplatin 6vinflunine 5enfortumab vedotin 5atezolizumab 5Vinblastine 5Radiotherapy 5Methotrexate 5Magnetic Resonance Spectroscopy 5Fluorouracil 5Cystectomy 5durvalumab 4Surgical Procedures, Operative 4Nivolumab 4Transurethral Resection of Bladder 3Specimen Handling 3Selenium 3Radiation 3Filgrastim 3Cystoscopy 3BCG Connaught 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Urinary Bladder Neoplasms × Nivolumab × Clear all
NCT03661320 2026-04-15

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Bristol-Myers Squibb

Phase 3 Active not recruiting
855 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

University of Pittsburgh

Phase 3 Completed
161 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT04149574 2025-09-16

CheckMate 7G8

Bristol-Myers Squibb

Phase 3 Terminated
13 enrolled 11 charts
Genitourinary

Urinary Bladder Neoplasms

NCT04209114 2024-06-27

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Bristol-Myers Squibb

Phase 3 Completed
114 enrolled 17 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡